A Phase I, Open-Label, Pharmacokinetic, Dose-Escalation Study of Cenobamate (YKP3089) in Pediatric Subjects With Partial-Onset Seizures
Latest Information Update: 11 Jul 2024
At a glance
- Drugs Cenobamate (Primary)
- Indications Partial epilepsies; Seizures
- Focus Pharmacokinetics
- Sponsors SK Life Science
- 20 Dec 2022 Planned End Date changed from 1 Dec 2022 to 1 Oct 2024.
- 20 Dec 2022 Planned primary completion date changed from 1 Dec 2022 to 1 Jul 2024.
- 31 May 2021 New trial record